【摘要】 目的观察万拉法新治疗社交焦虑症的疗效和安全性。方法采用万拉法新对符合DSM-Ⅳ诊断标准的44例社交焦虑症门诊患者进行治疗,治疗第8周末的药物平均剂量为(105.8±45.3 mg.d-1);采用L iebow itz社交焦虑量表(LSAS)、汉密尔顿焦虑量表(HAMA)及临床疗效总评量表(病情的严重程度)(CG I-SI)评定疗效,副反应症状量表(TESS)来评价药物副反应;LSAS的减分率≥75%为临床痊愈,50%~74%为显著进步,25%~49%为好转,≤25%为无效;分别于治疗前、治疗第1、2、4、8周末各评定一次。结果治疗第1周末,LSAS的焦虑因子分及HAMA量表分都有显著下降(P<0.05,P<0.01);治疗第2周末,LSAS总分、回避因子分,CG I-SI量表分均显著下降(P<0.01);治疗第8周末,显效(临床痊愈+显著进步)率为85.7%;药物副反应轻微。结论万拉法新治疗社交焦虑症有效,耐受性良好。更多还原

【Abstract】 Aim To observe the effect and safety of venlafaxine on the treatment of social anxiety disorder.Methods 44 outpatients of social anxiety disorder who meet the criteria of DSM-Ⅳ were treated with Venlafaxine. The average dose at the end of the 8th week is 105.8±45.3 mg·d~-~1.Liebowitz social anxiety scale(LSAS),HAMA,CGI-SI were used to evaluate the effect and TESS was used to evaluate the adverse reaction.Decreasing rate of LSAS above 75% ranked as clinical recovery,50%~74% as remarkably progress,25%~49% as responsive and below 25% as futile.Assessment was conducted before and after 1 week, 2 weeks,4 weeks and 8 weeks of treatment respectively.Results Scores of anxiety factor in LSAS and HAMA were both decreased significantly(P<0.05,P<0.01) after one week’s treatment.Total scores of LSAS,avoid factor and CGT-ST all dropped remarkably(P<0.01) after two weeks’ treatment and the valid rate was 85.7% with mild adverse reactions after eight weeks’ treatment.Conclusion Venlafaxine is effective and well tolerant on the treatment of SAD.更多还原